News Release

ZymoGenetics to Webcast Presentations at the Life Science Innovation Northwest and Barclays Capital Healthcare Conferences

March 10, 2010

SEATTLE, Mar 10, 2010 (BUSINESS WIRE) -- ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that members of senior management will provide updates on company activities at the following conferences:

• Stephen W. Zaruby, President, will present at the Life Science Innovation Northwest conference in Seattle on Tuesday, March 16, 2010 at 9:30 a.m. Pacific Time.
• James A. Johnson, Executive Vice President and Chief Financial Officer, will present at the Barclays Capital Global Healthcare Conference in Miami Beach on Tuesday, March 23, 2010at 2:30 p.m. Eastern Time.

Live webcasts of the presentations can be accessed by going to: http://www.zymogenetics.com. The webcasts will be archived for 30 days.

About ZymoGenetics

ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. In the past, ZymoGenetics has conducted extensive discovery research to identify potential product candidates, with a primary focus in autoimmune disorders and oncology. After a series of strategic initiatives undertaken in 2008 and 2009, ZymoGenetics is now focused on developing and commercializing a limited number of product candidates, which it believes have substantial medical and commercial potential. ZymoGenetics has developed and is marketing RECOTHROM(R) Thrombin, topical (Recombinant) in the United States. ZymoGenetics has two product candidates in clinical development: PEG-Interferon lambda, being studied in collaboration with Bristol Myers Squibb (BMS) for treatment of hepatitis C virus (HCV) infection, and IL-21, being tested by ZymoGenetics as a potential treatment for metastatic melanoma. In addition, ZymoGenetics has an anti-IL-31 monoclonal antibody in preclinical development, which it expects to test initially as a treatment for atopic dermatitis. Several of the product candidates previously identified through ZymoGenetics' discovery research efforts have been licensed to and are being developed by third parties, including Merck Serono and Novo Nordisk. ZymoGenetics is eligible to receive milestone payments and royalties related to these assets. For further information, visit http://www.zymogenetics.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics.These statements are not guarantees of future actions and involve uncertainties that are difficult to predict. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.

SOURCE: ZymoGenetics, Inc.

ZymoGenetics, Inc.
Media and Investor Relations
Susan W. Specht, 206-442-6592